Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24742739

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2014 May
First author
André F

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 May;15(6):541-2. doi: 10.1016/S1470-2045(14)70181-0.
    note
    Source null
    related pmid
    24807856
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6.
    note
    Source null
    related pmid
    24988929
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2014 Jul;15(8):e304-5. doi: 10.1016/S1470-2045(14)70288-8.
    note
    Source null
    related pmid
    24988930
    relationship
    Comment in

Authors and identifiers

  1. name
    André F
    type
    Author
  2. name
    O'Regan R
    type
    Author
  3. name
    Ozguroglu M
    type
    Author
  4. name
    Toi M
    type
    Author
  5. name
    Xu B
    type
    Author
  6. name
    Jerusalem G
    type
    Author
  7. name
    Masuda N
    type
    Author
  8. name
    Wilks S
    type
    Author
  9. name
    Arena F
    type
    Author
  10. name
    Isaacs C
    type
    Author
  11. name
    Yap YS
    type
    Author
  12. name
    Papai Z
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    André F
    type
    Author
  2. name
    O'Regan R
    type
    Author
  3. name
    Ozguroglu M
    type
    Author
  4. name
    Toi M
    type
    Author
  5. name
    Xu B
    type
    Author
  6. name
    Jerusalem G
    type
    Author
  7. name
    Masuda N
    type
    Author
  8. name
    Wilks S
    type
    Author
  9. name
    Arena F
    type
    Author
  10. name
    Isaacs C
    type
    Author
  11. name
    Yap YS
    type
    Author
  12. name
    Papai Z
    type
    Author
bibliography ids
  1. nci-bib-83d0c85d438739702ba65891
book metadata
content sha256
ceb46a4ff8e0e4c4b38518d5de8cd1552c122a3edaa76e9e50d2e2e36d44077f
document type
citation
dois
  1. 10.1016/S1470-2045(14)70138-X
electronic publication date
display
2014 Apr 14
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:24742739
immutable id
pubmed:24742739@ceb46a4ff8e0e4c4b38518d5de8cd1552c122a3edaa76e9e50d2e2e36d44077f
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
580-91
volume
15
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 May;15(6):541-2. doi: 10.1016/S1470-2045(14)70181-0.
    note
    Source null
    related pmid
    24807856
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6.
    note
    Source null
    related pmid
    24988929
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2014 Jul;15(8):e304-5. doi: 10.1016/S1470-2045(14)70288-8.
    note
    Source null
    related pmid
    24988930
    relationship
    Comment in
outcomes validated
false
pmid
24742739
provenance
batch id
063b6c38419f18d4021f
provider
NCBI PubMed ESummary
record sha256
39f315f6d34f3c86f7d8c3ec1f476745ec587bd849798f6ffb3cd7e6f21cb1e2
response sha256
5abcae41e9384a85f92695ef76b244ffd933f07a58a51082c160af8743d196ad
retrieved at
2026-09-09T23:47:02.607425+00:00
publication date
display
2014 May
precision
month
year
2014
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24742739/
title
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

Preserved source evidence · Not medical advice